HOOKIPA Pharma Management
Management criteria checks 3/4
HOOKIPA Pharma's CEO is Joern Aldag, appointed in Jun 2016, has a tenure of 7.83 years. total yearly compensation is $1.25M, comprised of 31.2% salary and 68.8% bonuses, including company stock and options. directly owns 0.073% of the company’s shares, worth $50.87K. The average tenure of the management team and the board of directors is 7.4 years and 5 years respectively.
Key information
Joern Aldag
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 31.2% |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.07% |
| Management average tenure | 7.4yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25Newsflash: HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Have Been Trimming Their Revenue Forecasts
May 18Hookipa: Speculative Biotech With Key Catalysts In 2022
Mar 29Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Oct 01Checking Back In On HOOKIPA Pharma
Jun 22Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers
Jun 08Does HOOKIPA Pharma (NASDAQ:HOOK) Have A Healthy Balance Sheet?
Apr 19If You Had Bought HOOKIPA Pharma (NASDAQ:HOOK) Shares A Year Ago You'd Have Earned 64% Returns
Mar 15What Kind Of Shareholders Hold The Majority In HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Shares?
Jan 22
Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
Dec 31Introducing HOOKIPA Pharma (NASDAQ:HOOK), A Stock That Climbed 55% In The Last Year
Dec 11HOOKIPA Pharma prices public offering of common stock and preferred stock
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$82m |
| Sep 30 2023 | n/a | n/a | -US$69m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$67m |
| Dec 31 2022 | US$1m | US$390k | -US$65m |
| Sep 30 2022 | n/a | n/a | -US$74m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$76m |
| Dec 31 2021 | US$3m | US$572k | -US$76m |
| Sep 30 2021 | n/a | n/a | -US$67m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$50m |
| Dec 31 2020 | US$2m | US$495k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$42m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$45m |
| Dec 31 2019 | US$6m | US$469k | -US$43m |
| Sep 30 2019 | n/a | n/a | -US$35m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | US$548k | US$362k | -US$16m |
| Dec 31 2017 | US$542k | US$339k | -US$13m |
Compensation vs Market: Joern's total compensation ($USD1.25M) is above average for companies of similar size in the US market ($USD677.87K).
Compensation vs Earnings: Joern's compensation has been consistent with company performance over the past year.
CEO
Joern Aldag (64 yo)
7.8yrs
Tenure
US$1,250,408
Compensation
Mr. Joern Aldag has been Chief Executive Officer at Hookipa Biotech GmbH since June 16, 2016. He has been a Director of Hookipa Pharma Inc. since December 2017 and is its Chief Executive Officer since June...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.8yrs | US$1.25m | 0.073% $ 50.9k | |
| CFO & Director | 7yrs | US$715.16k | 0.044% $ 30.5k | |
| Co-Founder | 13.3yrs | no data | no data | |
| Co-Founder | 13.3yrs | no data | no data | |
| Co-Founder | 13.3yrs | no data | no data | |
| Chief Operations Officer | less than a year | no data | no data | |
| Chief Scientific Officer | 2.1yrs | no data | no data | |
| Executive Director of Investor Relations | no data | no data | no data | |
| Executive Director of Communications | no data | no data | no data | |
| Chief Development Officer | no data | no data | no data | |
| Corporate Secretary | no data | no data | no data |
7.4yrs
Average Tenure
55yo
Average Age
Experienced Management: HOOK's management team is seasoned and experienced (7.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$1.25m | 0.073% $ 50.9k | |
| CFO & Director | 5.8yrs | US$715.16k | 0.044% $ 30.5k | |
| Independent Chairman of the Board | 7.3yrs | US$133.25k | 0.0092% $ 6.5k | |
| Scientific Advisory Member | 3.8yrs | US$23.76k | no data | |
| Director | 1.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 5.4yrs | US$70.37k | 0.0050% $ 3.5k | |
| Independent Director | 5yrs | US$70.37k | 0.0046% $ 3.2k | |
| Independent Non-Executive Director | 2yrs | US$77.65k | no data |
5.0yrs
Average Tenure
60yo
Average Age
Experienced Board: HOOK's board of directors are considered experienced (5 years average tenure).